EGFR and non-small cell lung carcinoma: In the recent NEJ026 study, a randomized open‐label phase 3 study, EGFR mutation‐positive NSCLC patients who received bevacizumab (a humanized monoclonal antibody to vascular endothelial growth factor [VEGF]) plus erlotinib combination therapy showed significantly prolonged progression‐free survival (PFS) compared with those who received erlotinib monotherapy.6